Annual EBITDA
-$11.33 M
+$6.80 M+37.50%
March 1, 2024
Summary
- As of February 8, 2025, GRCE annual EBITDA is -$11.33 million, with the most recent change of +$6.80 million (+37.50%) on March 1, 2024.
- During the last 3 years, GRCE annual EBITDA has fallen by -$1.53 million (-15.68%).
- GRCE annual EBITDA is now -640.47% below its all-time high of -$1.53 million, reached on February 1, 2010.
Performance
GRCE EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$4.83 M
+$133.00 K+2.68%
September 1, 2024
Summary
- As of February 8, 2025, GRCE quarterly EBITDA is -$4.83 million, with the most recent change of +$133.00 thousand (+2.68%) on September 1, 2024.
- Over the past year, GRCE quarterly EBITDA has dropped by -$1.79 million (-58.74%).
- GRCE quarterly EBITDA is now -127.96% below its all-time high of $17.27 million, reached on March 1, 2020.
Performance
GRCE Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$16.06 M
-$2.74 M-20.56%
September 1, 2024
Summary
- As of February 8, 2025, GRCE TTM EBITDA is -$16.06 million, with the most recent change of -$2.74 million (-20.56%) on September 1, 2024.
- Over the past year, GRCE TTM EBITDA has dropped by -$3.81 million (-31.11%).
- GRCE TTM EBITDA is now -271.45% below its all-time high of $9.37 million, reached on December 1, 2020.
Performance
GRCE TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
GRCE EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +37.5% | -58.7% | -31.1% |
| 3 y3 years | -15.7% | +5.7% | +12.3% |
| 5 y5 years | +69.2% | +76.5% | -71.5% |
GRCE EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -15.7% | +37.5% | -131.1% | +5.7% | -41.9% | +12.3% |
| 5 y | 5-year | -15.7% | +69.2% | -128.0% | +57.9% | -271.4% | +69.8% |
| alltime | all time | -640.5% | +69.2% | -128.0% | +76.5% | -271.4% | +69.8% |
Grace Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$4.83 M(-2.7%) | -$16.06 M(+20.6%) |
| Jun 2024 | - | -$4.96 M(+53.7%) | -$13.32 M(+17.7%) |
| Mar 2024 | -$11.33 M(-37.5%) | -$3.23 M(+6.1%) | -$11.32 M(-7.6%) |
| Dec 2023 | - | -$3.04 M(+45.6%) | -$12.25 M(-8.8%) |
| Sep 2023 | - | -$2.09 M(-29.4%) | -$13.43 M(-18.4%) |
| Jun 2023 | - | -$2.96 M(-28.7%) | -$16.46 M(-8.9%) |
| Mar 2023 | -$18.12 M(+18.1%) | -$4.16 M(-1.6%) | -$18.06 M(-1.3%) |
| Dec 2022 | - | -$4.22 M(-17.5%) | -$18.31 M(0.0%) |
| Sep 2022 | - | -$5.12 M(+12.2%) | -$18.31 M(+9.3%) |
| Jun 2022 | - | -$4.56 M(+3.6%) | -$16.76 M(+9.2%) |
| Mar 2022 | -$15.34 M(+56.7%) | -$4.40 M(+4.2%) | -$15.34 M(+19.6%) |
| Dec 2021 | - | -$4.22 M(+18.4%) | -$12.82 M(+21.4%) |
| Sep 2021 | - | -$3.57 M(+13.4%) | -$10.56 M(+12.8%) |
| Jun 2021 | - | -$3.15 M(+66.8%) | -$9.36 M(-4.4%) |
| Mar 2021 | -$9.79 M(-57.3%) | -$1.89 M(-4.0%) | -$9.79 M(-204.5%) |
| Dec 2020 | - | -$1.96 M(-17.1%) | $9.37 M(-6651.0%) |
| Sep 2020 | - | -$2.37 M(-33.7%) | -$143.00 K(-99.2%) |
| Jun 2020 | - | -$3.57 M(-120.7%) | -$18.31 M(-20.2%) |
| Mar 2020 | -$22.95 M(-37.6%) | $17.27 M(-250.5%) | -$22.95 M(-56.9%) |
| Dec 2019 | - | -$11.47 M(-44.1%) | -$53.19 M(+19.5%) |
| Sep 2019 | - | -$20.53 M(+150.1%) | -$44.50 M(+8.7%) |
| Jun 2019 | - | -$8.21 M(-36.7%) | -$40.96 M(+8.3%) |
| Mar 2019 | -$36.76 M(+157.0%) | -$12.98 M(+365.7%) | -$37.80 M(+24.7%) |
| Dec 2018 | - | -$2.79 M(-83.6%) | -$30.31 M(-4.5%) |
| Sep 2018 | - | -$16.99 M(+236.2%) | -$31.75 M(+78.5%) |
| Jun 2018 | - | -$5.05 M(-7.9%) | -$17.79 M(+24.5%) |
| Mar 2018 | -$14.30 M(+121.8%) | -$5.49 M(+29.8%) | -$14.29 M(+62.3%) |
| Dec 2017 | - | -$4.23 M(+39.9%) | -$8.80 M(+49.3%) |
| Sep 2017 | - | -$3.02 M(+94.5%) | -$5.90 M(+40.9%) |
| Jun 2017 | - | -$1.55 M(+17.5%) | -$4.18 M(-22.1%) |
| Mar 2017 | -$6.45 M | - | - |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Nov 2016 | - | -$1.32 M(+1.0%) | -$5.37 M(+2.5%) |
| Aug 2016 | - | -$1.31 M(-27.3%) | -$5.24 M(+18.6%) |
| May 2016 | - | -$1.80 M(+91.4%) | -$4.42 M(+51.3%) |
| Feb 2016 | -$2.89 M(-64.0%) | -$941.50 K(-20.8%) | -$2.92 M(-75.9%) |
| Nov 2015 | - | -$1.19 M(+144.0%) | -$12.12 M(+55.5%) |
| Aug 2015 | - | -$487.10 K(+60.6%) | -$7.80 M(-23.4%) |
| May 2015 | - | -$303.30 K(-97.0%) | -$10.18 M(+25.8%) |
| Feb 2015 | -$8.04 M(-9.1%) | -$10.14 M(-423.1%) | -$8.09 M(>+9900.0%) |
| Nov 2014 | - | $3.14 M(-209.2%) | -$37.70 K(-99.3%) |
| Aug 2014 | - | -$2.87 M(-260.8%) | -$5.66 M(+5.2%) |
| May 2014 | - | $1.79 M(-185.5%) | -$5.38 M(-39.6%) |
| Feb 2014 | -$8.84 M(+45.4%) | -$2.09 M(-15.7%) | -$8.91 M(+5.7%) |
| Nov 2013 | - | -$2.48 M(-4.4%) | -$8.43 M(+13.9%) |
| Aug 2013 | - | -$2.59 M(+48.7%) | -$7.40 M(+15.6%) |
| May 2013 | - | -$1.74 M(+8.2%) | -$6.41 M(+6.3%) |
| Feb 2013 | -$6.08 M(+3.8%) | -$1.61 M(+10.9%) | -$6.03 M(+1.0%) |
| Nov 2012 | - | -$1.45 M(-9.0%) | -$5.97 M(-8.0%) |
| Aug 2012 | - | -$1.60 M(+16.8%) | -$6.49 M(+0.2%) |
| May 2012 | - | -$1.37 M(-11.8%) | -$6.48 M(+8.2%) |
| Feb 2012 | -$5.86 M(+145.2%) | -$1.55 M(-21.5%) | -$5.99 M(+12.0%) |
| Nov 2011 | - | -$1.97 M(+24.5%) | -$5.35 M(+34.8%) |
| Aug 2011 | - | -$1.59 M(+81.1%) | -$3.97 M(+38.3%) |
| May 2011 | - | -$876.20 K(-3.8%) | -$2.87 M(+22.4%) |
| Feb 2011 | -$2.39 M(+56.2%) | -$910.40 K(+52.9%) | -$2.34 M(+26.7%) |
| Nov 2010 | - | -$595.60 K(+22.3%) | -$1.85 M(+13.4%) |
| Aug 2010 | - | -$486.90 K(+38.8%) | -$1.63 M(+2.3%) |
| May 2010 | - | -$350.70 K(-15.7%) | -$1.59 M(+5.8%) |
| Feb 2010 | -$1.53 M | -$415.90 K(+10.3%) | -$1.51 M(+38.2%) |
| Nov 2009 | - | -$376.90 K(-16.2%) | -$1.09 M(+21.0%) |
| Aug 2009 | - | -$449.80 K(+71.0%) | -$900.90 K(+99.7%) |
| May 2009 | - | -$263.00 K(+39.8%) | -$451.10 K(+139.8%) |
| Nov 2008 | - | -$188.10 K | -$188.10 K |
FAQ
- What is Grace Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Grace Therapeutics?
- What is Grace Therapeutics annual EBITDA year-on-year change?
- What is Grace Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Grace Therapeutics?
- What is Grace Therapeutics quarterly EBITDA year-on-year change?
- What is Grace Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Grace Therapeutics?
- What is Grace Therapeutics TTM EBITDA year-on-year change?
What is Grace Therapeutics annual EBITDA?
The current annual EBITDA of GRCE is -$11.33 M
What is the all time high annual EBITDA for Grace Therapeutics?
Grace Therapeutics all-time high annual EBITDA is -$1.53 M
What is Grace Therapeutics annual EBITDA year-on-year change?
Over the past year, GRCE annual EBITDA has changed by +$6.80 M (+37.50%)
What is Grace Therapeutics quarterly EBITDA?
The current quarterly EBITDA of GRCE is -$4.83 M
What is the all time high quarterly EBITDA for Grace Therapeutics?
Grace Therapeutics all-time high quarterly EBITDA is $17.27 M
What is Grace Therapeutics quarterly EBITDA year-on-year change?
Over the past year, GRCE quarterly EBITDA has changed by -$1.79 M (-58.74%)
What is Grace Therapeutics TTM EBITDA?
The current TTM EBITDA of GRCE is -$16.06 M
What is the all time high TTM EBITDA for Grace Therapeutics?
Grace Therapeutics all-time high TTM EBITDA is $9.37 M
What is Grace Therapeutics TTM EBITDA year-on-year change?
Over the past year, GRCE TTM EBITDA has changed by -$3.81 M (-31.11%)